Research Article

Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer

Published: April 26, 2016
Genet. Mol. Res. 15(2): gmr7702 DOI: https://doi.org/10.4238/gmr.15027702
Cite this Article:
X. Chen, X.S. Liu, H.Y. Liu, Y.Y. Lu, Y. Li, X. Chen, X.S. Liu, H.Y. Liu, Y.Y. Lu, Y. Li, X. Chen, X.S. Liu, H.Y. Liu, Y.Y. Lu, Y. Li (2016). Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer. Genet. Mol. Res. 15(2): gmr7702. https://doi.org/10.4238/gmr.15027702
2,625 views

Abstract

Deregulation of microRNAs (miRNAs) is implicated in the initiation and progression of gastric cancer (GC). Previous studies have demonstrated that miR-204 was downregulated in GC tissues. However, its expression profile in serum samples and its potential for clinical value remain unknown. Real-time PCR was performed to evaluate the expression level of serum miR-204 in patients with GC. The association between serum miR-204 expression level and the clinical outcome of GC was then investigated. Our results showed that the expression of miR-204 in serum samples from GC patients was significantly lower than that in the healthy controls (P < 0.01). Serum miR-204 expression level of GC patients was significantly upregulated after receiving surgical resection (P < 0.01). In addition, serum miR-204 was associated with lymph node metastasis (P = 0.016), tumor differentiation (P = 0.001), and TNM stage (P = 0.005). GC patients with low serum miR-204 expression had shorter overall survival than those with high serum miR-204 expression (P = 0.004). Multivariate analysis revealed that serum miR-204 expression level was an independent risk factor for this malignant disease (HR = 3.629, 95%CI = 2.828-8.146, P = 0.015). In conclusion, our findings indicate that serum miR-204 may be employed as a novel biomarker for monitoring the treatment response and predicting the prognosis of GC.

Deregulation of microRNAs (miRNAs) is implicated in the initiation and progression of gastric cancer (GC). Previous studies have demonstrated that miR-204 was downregulated in GC tissues. However, its expression profile in serum samples and its potential for clinical value remain unknown. Real-time PCR was performed to evaluate the expression level of serum miR-204 in patients with GC. The association between serum miR-204 expression level and the clinical outcome of GC was then investigated. Our results showed that the expression of miR-204 in serum samples from GC patients was significantly lower than that in the healthy controls (P

About the Authors